文献速递免疫规划传染病防控与疫情报告

猪链球菌双突变活疫苗对2型和7型的交叉保护

Immunogenicity and cross-protective efficacy of double-mutant Streptococcus suis ΔSspepO/ΔSspspC serotypes 2 and 7.
PubMed 文献 · Vaccine · 2019-03-20

该研究在猪中评估了猪链球菌双突变株ΔSspepO/ΔSspspC经肌肉注射后的免疫原性与交叉保护效果,结果显示可诱导可检测的抗体产生,对2型攻毒提供100%保护、对7型提供60%保护,并诱导针对2型和7型的调理抗体,IgG亚类分析显示Th1和Th2反应均被诱导但以IgG2a(Th1)为主。

要点

  • 双突变株ΔSspepO/ΔSspspC可诱导猪产生可检测抗体。
  • 对2型攻毒100%保护,对7型攻毒60%保护。
  • 诱导针对2型和7型的调理抗体,以IgG2a(Th1)反应为主。

核心结论

  • 双突变株ΔSspepO/ΔSspspC作为活疫苗候选可对猪链球菌2型和7型提供交叉保护。

研究设计与样本

  • 在猪中经肌肉注射活疫苗ΔSspepO/ΔSspspC,通过临床、细菌学、血清学及剖检评估保护。

主要发现

  • 对2型攻毒提供100%保护,对7型攻毒提供60%保护。
  • 诱导针对2型和7型的调理抗体。
  • IgG1和IgG2a均升高,IgG2a(Th1)反应占优势。

关键数值与推荐

  • 2型攻毒保护率100%,7型攻毒保护率60%。

临床怎么用

  • 提示该双突变活疫苗可作为预防猪链球菌2型和7型感染的候选,需进一步评估可行性与交叉保护。

局限性

  • 研究仅在猪中进行,需进一步研究评估候选疫苗及交叉保护可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Streptococcus suis serotype 2 (S. suis 2) is a major pathogen causing streptococcosis in swine, resulting in significant losses in swine breeding worldwide. We previously reported that the non-antibiotic-resistant double-mutant strain ΔSspepO/ΔSspspC can be used as a live vaccine, providing effective protection against S. suis 2 infections in mice. This study aimed to understand the characteristics of streptococcosis and develop vaccine candidates for immunization. Intramuscular injection of live S. suis ΔSspepO/ΔSspspC in pigs induced discernable antibody production and provided cross-protection against challenges by a type 2 strain (100% protection) and a type 7 strain (60% protection). Protection was evaluated via clinical, bacteriological, serological, and post-mortem examinations. Furthermore, vaccination induced the production of opsonizing antibodies against serotypes 2 and 7. Analysis of IgG subclasses (IgG1 and IgG2a) revealed that both Th1 and Th2 responses were induced by S. suis ΔSspepO/ΔSspspC, although the IgG2a (Th1) response predominated over the IgG1 (Th2) response. This study is the first, to our knowledge, to establish a live vaccine candidate to protect against two major S. suis serotypes. Further studies are required to assess these candidate vaccines and examine their feasibility in providing cross-protection against S. suis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hu J, Xu J, Liu F, et al. Immunogenicity and cross-protective efficacy of double-mutant Streptococcus suis ΔSspepO/ΔSspspC serotypes 2 and 7. Vaccine. 2019. PMID: 30902483. doi:10.1016/j.vaccine.2019.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。